Zimmer Biomet Announces Third Quarter 2026 Financial Results
Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% reported and 3.7% constant currency, with diluted EPS of $1.00 (down 13.8%) and adjusted EPS of $1.90, flat year-over-year. Diversification franchises carried the quarter: Hips grew 6.0%, S.E.T. 6.8%, and Technology & Data/Bone Cement/Surgical 11.9%, while Knees declined 3.1%. Free cash flow was $372.4 million on $560.0 million of operating cash flow.
Key figures
- Eps
- 1
- Revenue
- 2062900000
- Guidance
- FY2026 reported revenue change 4.4%-4.9% (from 3.9%-4.9%); constant currency revenue 4.1%-4.6% (from 3.4%-4.4%); organic constant currency 3.0%-3.5% (from 2.25%-3.25%); adjusted diluted EPS $8.50-$8.60 (from $8.47-$8.59)
- Revenue Yoy
- 3.1%
- Fcf
- 372400000
- Adjusted eps
- 1.9
- Net earnings
- 191600000
- Hip sales change
- 6.0%
- Set sales change
- 6.8%
- Knee sales change
- -3.1%
- Operating cash flow
- 560000000
- Adjusted net earnings
- 362800000
- Tech data cement surgical change
- 11.9%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.